Antibodies to NTB-A
Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.
1. An isolated antibody that specifically binds NTB-A or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:5 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:7.
2. The antibody of claim 1 , which is chimeric.
3. A pharmaceutical composition comprising the antibody of claim 1 , further comprising a suitable carrier.
4. The antibody of claim 1 , wherein said antibody is murine anti-NTB-A monoclonal antibody 480.12 that is produced by a hybridoma having ATCC Deposit No. PTA-7832.
5. The antibody of claim 1 , wherein the heavy chain variable domain and the light chain variable domain are connected by a flexible linker to form a single chain antibody.
6. The antibody of claim 5 , which is an scFv antibody.
7. The antibody or antigen-binding fragment thereof of claim 1 , which is selected from the group consisting of a Fab antibody, a Fab′ antibody, a (Fab′) 2 antibody, and a chimeric antibody.
8. A pharmaceutical composition comprising the antibody of claim 1 , further comprising at least one therapeutic agent.
9. The hybridoma cell line 480.12 deposited with the ATCC as accession number PTA-7832.
10. An isolated antibody that specifically binds NTB-A or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain comprising the complementarity determining region (CDR) amino acid sequences of SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26; and a light chain variable domain comprising the CDR amino acid sequences of SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29.
11. The antibody of claim 10 , wherein the heavy chain variable domain and the light chain variable domain are connected by a flexible linker to form a single chain antibody.
12. The antibody of claim 11 , which is an scFv antibody.
13. The antibody or antigen-binding fragment thereof of claim 10 , which is selected from the group consisting of a Fab antibody, a Fab′ antibody, a (Fab′) 2 antibody, a humanized antibody, and a chimeric antibody.
14. The antibody of claim 10 , which is humanized.
15. A pharmaceutical composition comprising the antibody of claim 10 , further comprising a suitable carrier.
16. A pharmaceutical composition comprising the antibody of claim 10 , further comprising at least one therapeutic agent.
17. An isolated cell line that produces the antibody of claim 10 .